ReviewJournal of Crohn's & colitis2025
Environmental risk factors of inflammatory bowel disease: toward a strategy of preventative health.
Review in Journal of Crohn's & colitis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Climate classification, sociodemographic development, and the burden of inflammatory bowel disease in tropical countries.Tropical medicine and health · 2026Article
- Precision nutrition for the prevention and management of inflammatory bowel disease.Nature reviews. Gastroenterology & hepatology · 2026Review
- Modifiable lifestyle factors in early life and inflammatory bowel disease risk in two birth cohorts.Journal of Crohn's & colitis · 2026Article
- Caregiver contribution to patient self‑care and quality of life among informal carers of adult patients with inflammatory bowel disease: a cross‑sectional study.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Current approaches to disease severity and therapy effectiveness assessment in patients with inflammatory bowel disease.World journal of gastrointestinal pharmacology and therapeutics · 2026Review
- Probable Association Between Hidradenitis Suppurativa and Inflammatory Bowel Disease: A Case Report.Cureus · 2026Article
- Inflammatory bowel disease phenotypes in diverse populations: a global comparative analysis.Journal of Crohn's & colitis · 2026Article
- Beyond the Gut: Extra-Enteric Digestive Manifestations of Inflammatory Bowel Disease-A Personalized Medicine Perspective and Comprehensive Review.Journal of personalized medicine · 2026Review
- Selective Drug-Free Active Surveillance in Ulcerative Colitis: Biomarker-Guided, Patient-Centered Approach.JGH open : an open access journal of gastroenterology and hepatology · 2026Review
- Prediction and Prevention of Inflammatory Bowel Disease: A Call to Action.Gastroenterology · 2026Article
- Disease-modifying efficacy of alginate-microencapsulated probiotics in an animal model of ulcerative colitis.Archives of microbiology · 2026Article
- From dysbiosis to precision medicine: targeting the microbial-metabolic axis in IBD management.Frontiers in cellular and infection microbiology · 2026Review
- Integrated Multiomics Elucidates Molecular Mechanisms of Bisphenol A in Exacerbating Crohn's Disease.Mediators of inflammation · 2026Article
- Shared inflammatory architecture and therapeutic tensions between psoriasis and Crohn's disease.Frontiers in immunology · 2026Review
- KASID and Intestinal Research journal: a central academic hub for research of intestinal diseases in the Asia-Pacific region.Intestinal research · 2026Article
- Trends in the disease burden of inflammatory bowel disease among the working-age population (20-64 years) from 1990 to 2021: a population-based study.BMC gastroenterology · 2025Article
- TRENDS IN THE ULCERATIVE COLITIS TO CROHN'S DISEASE INCIDENCE RATIO ARE DISTINCT BETWEEN EPIDEMIOLOGIC STAGES OF INFLAMMATORY BOWEL DISEASE.The American journal of gastroenterology · 2025Article
- Vedolizumab Versus Other Biologics and the Risk of Venous Thromboembolism in Patients with Pediatric-Onset Inflammatory Bowel Diseases: A Target Trial Emulation Study.Paediatric drugs · 2025Article
- IBD Prediction Is Possible, but How Far Are We from Implementing It?Inflammatory bowel diseases · 2025Review
- The global burden of inflammatory bowel disease: from 2025 to 2045.Nature reviews. Gastroenterology & hepatology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pathogenesis of inflammatory bowel disease (IBD) involves a complex interplay between genetic, environmental, and microbial factors. Many of these environmental determinants are modifiable, offering opportunities to prevent disease or delay its onset. Advances in the study of preclinical IBD cohorts offer the potential to identify biomarkers that predict individuals at high risk of developing IBD, enabling targeted environmental interventions aimed at reducing IBD incidence. This review summarizes findings from 79 meta-analyses on modifiable environmental factors associated with the development of IBD. Identified risk factors include smoking, Western diets, ultra-processed foods, and early life antibiotic use, while protective factors include breastfeeding, Mediterranean diets rich in fiber, plant-based foods, and fish, along with an active physical lifestyle. Despite the promise shown by observational data, interventional or randomized controlled studies evaluating the efficacy of modifying environmental risk factors remain limited and mostly focus on dietary intervention. This review aims to inform the design of higher quality interventional and randomized controlled studies for disease prevention while providing actionable guidance to healthcare providers on reducing the risk of developing IBD through environmental modifications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.